Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera

Leukemia Research

Volumn 31, Issue 1, 2007, Pages 97-101

  Rossi, Davide ^a   Cortini, Francesca ^a   Deambrogi, Clara ^a   Barbieri, Caterina ^a   Cerri, Michaela ^a   Franceschetti, Silvia ^a   Conconi, Annarita ^a   Capello, Daniela ^a   Gaidano, Gianluca ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Chronic myeloproliferative disorders; Idiopathic erythrocytosis; JAK2; Polycythemia vera; Primary erythrocytosis

Indexed keywords

ACETYLSALICYLIC ACID; BUSULFAN; COMPLEMENTARY DNA; HYDROXYUREA; JANUS KINASE 2;

ADULT; AGED; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ERYTHROCYTOSIS; FEMALE; GENE MUTATION; HUMAN; MALE; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ASPIRIN; BONE MARROW; DIAGNOSIS, DIFFERENTIAL; DNA; FEMALE; GENETIC MARKERS; HUMANS; HYDROXYUREA; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; POLYCYTHEMIA; POLYCYTHEMIA VERA; RNA; TREATMENT OUTCOME;

EID: 33750743094     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.02.027     Document Type: Article

References (11)

1. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization Classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon
2. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. New Engl J Med 352 (2005) 1779-1790
3. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
4. Spivak J.L. Polycythemia vera: myths, mechanisms, and management. Blood 100 (2002) 4272-4290
5. Blacklock H.A., and Royle G.A. Idiopathic erythrocytosis-a declining entity. Br J Haematol 115 (2001) 774-781
6. van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukaemia. Leukemia 13 (1999) 1901-1928
7. Lemoine F., Najman A., Baillou C., Stachowiak J., Boffa G., Aegerter P., et al. A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia. Blood 68 (1986) 996-1002
8. Mitterbauer G., Winkler K., Gisslinger H., Geissler K., Lechner K., and Mannhalter C. Clonality analysis using X-chromosome inactivation at the human androgen receptor gene (Humara). Evaluation of large cohorts of patients with chronic myeloproliferative diseases, secondary neutrophilia, and reactive thrombocytosis. Am J Clin Pathol 112 (1999) 93-100
9. Wiktor A., Rybicki B.A., Piao Z.S., Shurafa M., Barthel B., Maeda K., et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer 27 (2000) 11-16
10. Levine R.L., Belisle C., Wadleigh M., Zahrieh D., Lee S., Chagnon P., et al. X-inactivation based clonality analysis and quantitative JAK2V617F assessment reveals a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F negative ET and MMM patients with clonal hematopoiesis. Blood 107 (2006) 4139-4141
11. Busque L., Mio R., Mattioli J., Brais E., Blais N., Lalonde Y., et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood 88 (1996) 59-65